Prolactin and sex hormones levels in males with Parkinson's disease

Acta Neurologica Scandinavica

Volumn 131, Issue 6, 2015, Pages 411-416

  Nitkowska, M ^a,c   Tomasiuk, R ^b   Czyzyk, M ^b   Friedman, A ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Mazowiecki Hospital Brodnowski   (Poland)

^c Czerniakowski Hospital   (Poland)

Author keywords

Movement disorder; Neuroendocrinology; Parkinson's disease

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; ESTRADIOL; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; PROLACTIN; ROPINIROLE; SEX HORMONE BINDING PROTEIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CHEMOLUMINESCENCE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; ESTRADIOL BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; MALE; MOOD; PARKINSON DISEASE; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; TESTOSTERONE BLOOD LEVEL; AFFECT; BLOOD; COGNITION; MIDDLE AGED; VERY ELDERLY;

ADULT; AFFECT; AGED; AGED, 80 AND OVER; COGNITION; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROLACTIN; TESTOSTERONE;

EID: 84926408889     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12334     Document Type: Article

References (35)

1. Mayeux R, Denaro J, Hemenegildo N. A population based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992;49:492-7.
2. Haaxma CA, Bloem BR, Borm GF. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:819-24.
3. Küppers E, Ivanova T, Karolczak M, Lazarov N, Föhr K, Beyer C. Classical and nonclassical estrogen action in the developing midbrain. Horm Behav 2001;40:196-202.
4. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007;72:381-405.
5. Cyr M, Calon F, Morissette M, Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 2002;27:12-27.
6. Sarkey S, Azcoitia I, Garcia-Segura LM, Garcia-Ovejero D, DonCarlos LL. Classical androgen receptors in non-classical sites in the brain. Horm Behav 2008;53:753-64.
7. Zhang Y, Champagne N, Beitel LK, Goodyer CG, Trifiro M, LeBlanc A. Estrogen and androgen protection of human neurons against intracellular amyloid beta1-42 toxicity through heat shock protein 70. J Neurosci 2004;24:5315-21.
8. Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2003;2:23-32.
9. Litvan I, Bhatia KP, Burn DJ et al. Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467-86.
10. Grosset K, Needleman F, Macphee G, Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004;19(11):1370-4.
11. Movement Disorder Society Task Force on Rating Scales for Parkinson's disease. UPDRS: status and recommendations. Mov Disord 2003;18:738-50.
12. Goetz CG. Rating scales for dyskinesias in Parkinson's disease. Mov Disord 1999;14(Suppl 1):48-53.
13. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
14. Howieson DB, Lezak MD, Loring DW. Orientation and attention Neuropsychological assessment. Oxford [Oxfordshire]: Oxford University Press ISBN 0-19-511121-4.
15. Beck AT, Ward CH, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-7.
16. Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N. "Self reported functioning and well being in patients with Parkinson's disease: comparison of the Short Form Health Survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39)". Age Ageing 1995;24:505-9.
17. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252(Suppl 4):IV37-42.
18. O'Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: the Massachusetts Male Aging Study (1987-2004). Exp Gerontol 2004;39:975-84.
19. Driscoll I, Hamilton DA, Yeo RA, Brooks WM, Sutherland RJ. Virtual navigation in humans: the impact of age, sex, and hormones on place learning. Horm Behav 2005;47:326-35.
20. Kampen DL, Sherwin BB. Estradiol is related to visual memory in healthy young men. Behav Neurosci 1996;110:613-7.
21. Lessov-Schlaggar CN, Reed T, Swan GE et al. Association of sex steroid hormones with brain morphology and cognition in healthy elderly men. Neurology 2005;65:1591-6.
22. LeBlanc ES, Wang PY, Janowsky JS et al. Association between sex steroids and cognition in elderly men. Clin Endocrinol (Oxf) 2010;72:393-403.
23. Kenangil G, Orken DN, Ur E, Forta H, Celik M. The relation of testosterone levels with fatigue and apathy in Parkinson's disease. Clin Neurol Neurosurg 2009;111:412-4.
24. Okun MS, DeLong MR, Hanfelt J, Gearing M, Levey A. Plasma testosterone levels in Alzheimer and Parkinson diseases. Neurology 2004;62:411-3.
25. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001;22:724-63.
26. Agnoli A, Baldassarre M, Ruggieri S, Falaschi P, Urso RD, Rocco A. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response. J Neural Transm 1981;51:123-34.
27. Schaefer S, Vogt T, Nowak T. Pituary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy. J Neuroendocrinol 2008;20:104-9.
28. Winkler AS, Landau S, Chaudhuri KR. Serum prolactin levels in Parkinson's disease and multiple system atrophy. Clin Auton Res 2002;12:393-8.
29. Kirkpatrick B, Tamminga CA. The endocrinology of extrapyramidal system disorders. Endocrinol Metab Clin North Am 1988;17:159-72.
30. Rastembegovic A, Sofic E, Wichart I. Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotic treatment in Parkinson's disease and related psychosis. Med Arh 2006;60:211-2.
31. Lawton NF, MacDermot J. Abnormal regulation of prolactin release in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1980;43:1012-5.
32. Eisler T, Thorner MO, MacLeod RM, Kaiser DL, Calne DB. Prolactin secretion in Parkinson disease. Neurology 1981;31:1356-9.
33. Martinez-Campos A, Giovannini P, Parati E, Novelli A, Caraceni T, Müller EE. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1116-23.
34. Ruggieri S, Falaschi P, Baldassarre M et al. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease. Neuropsychobiology 1982;8:102-8.
35. Polleri A, Masturzo P, Murialdo G, Carolei A. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans. Acta Endocrinol (Copenh) 1980;93:7-12.